Log in
NASDAQ:VXRT

Vaxart Competitors

$7.40
+0.51 (+7.40 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$7.09
Now: $7.40
$7.58
50-Day Range
$4.78
MA: $7.42
$10.75
52-Week Range
$0.26
Now: $7.40
$17.49
Volume11.05 million shs
Average Volume18.22 million shs
Market Capitalization$808.09 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.04

Competitors

Vaxart (NASDAQ:VXRT) Vs. IMVT, SRNE, RVMD, MESO, SWTX, and EDIT

Should you be buying VXRT stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Vaxart, including Immunovant (IMVT), Sorrento Therapeutics (SRNE), Revolution Medicines (RVMD), Mesoblast (MESO), SpringWorks Therapeutics (SWTX), and Editas Medicine (EDIT).

Immunovant (NASDAQ:IMVT) and Vaxart (NASDAQ:VXRT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Immunovant and Vaxart, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunovant001003.00
Vaxart00203.00

Immunovant currently has a consensus price target of $38.3636, indicating a potential upside of 7.67%. Vaxart has a consensus price target of $19.50, indicating a potential upside of 163.51%. Given Vaxart's higher possible upside, analysts plainly believe Vaxart is more favorable than Immunovant.

Insider & Institutional Ownership

33.9% of Immunovant shares are owned by institutional investors. Comparatively, 17.9% of Vaxart shares are owned by institutional investors. 0.2% of Immunovant shares are owned by company insiders. Comparatively, 36.7% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Immunovant and Vaxart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunovantN/AN/AN/A
Vaxart-281.50%-84.90%-44.67%

Earnings & Valuation

This table compares Immunovant and Vaxart's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunovantN/AN/AN/A($1.54)-23.14
Vaxart$9.86 million81.96$-18,650,000.00($0.86)-8.60

Immunovant has higher earnings, but lower revenue than Vaxart. Immunovant is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Sorrento Therapeutics (NASDAQ:SRNE) and Vaxart (NASDAQ:VXRT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Sorrento Therapeutics and Vaxart, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sorrento Therapeutics00303.00
Vaxart00203.00

Sorrento Therapeutics currently has a consensus price target of $25.00, indicating a potential upside of 159.47%. Vaxart has a consensus price target of $19.50, indicating a potential upside of 163.51%. Given Vaxart's higher possible upside, analysts plainly believe Vaxart is more favorable than Sorrento Therapeutics.

Volatility and Risk

Sorrento Therapeutics has a beta of 2.93, suggesting that its stock price is 193% more volatile than the S&P 500. Comparatively, Vaxart has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500.

Insider & Institutional Ownership

24.1% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 17.9% of Vaxart shares are owned by institutional investors. 3.4% of Sorrento Therapeutics shares are owned by company insiders. Comparatively, 36.7% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Sorrento Therapeutics and Vaxart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sorrento Therapeutics-760.19%-490.67%-38.31%
Vaxart-281.50%-84.90%-44.67%

Earnings & Valuation

This table compares Sorrento Therapeutics and Vaxart's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$31.43 million74.19$-292,070,000.00($2.12)-4.54
Vaxart$9.86 million81.96$-18,650,000.00($0.86)-8.60

Vaxart has lower revenue, but higher earnings than Sorrento Therapeutics. Vaxart is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Vaxart beats Sorrento Therapeutics on 7 of the 13 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Vaxart (NASDAQ:VXRT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Revolution Medicines and Vaxart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution MedicinesN/AN/AN/A
Vaxart-281.50%-84.90%-44.67%

Insider & Institutional Ownership

71.6% of Revolution Medicines shares are owned by institutional investors. Comparatively, 17.9% of Vaxart shares are owned by institutional investors. 36.7% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Revolution Medicines and Vaxart's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million43.31$-47,660,000.00N/AN/A
Vaxart$9.86 million81.96$-18,650,000.00($0.86)-8.60

Vaxart has lower revenue, but higher earnings than Revolution Medicines.

Analyst Recommendations

This is a summary of current recommendations and price targets for Revolution Medicines and Vaxart, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines01402.80
Vaxart00203.00

Revolution Medicines currently has a consensus price target of $43.25, indicating a potential upside of 31.58%. Vaxart has a consensus price target of $19.50, indicating a potential upside of 163.51%. Given Vaxart's stronger consensus rating and higher possible upside, analysts plainly believe Vaxart is more favorable than Revolution Medicines.

Summary

Revolution Medicines beats Vaxart on 6 of the 11 factors compared between the two stocks.

Mesoblast (NASDAQ:MESO) and Vaxart (NASDAQ:VXRT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Mesoblast and Vaxart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mesoblast-242.38%-15.49%-11.36%
Vaxart-281.50%-84.90%-44.67%

Insider and Institutional Ownership

2.5% of Mesoblast shares are held by institutional investors. Comparatively, 17.9% of Vaxart shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 36.7% of Vaxart shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Mesoblast and Vaxart's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$32.16 million63.98$-77,940,000.00($0.74)-23.70
Vaxart$9.86 million81.96$-18,650,000.00($0.86)-8.60

Vaxart has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Mesoblast has a beta of 3.64, suggesting that its stock price is 264% more volatile than the S&P 500. Comparatively, Vaxart has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Mesoblast and Vaxart, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mesoblast00503.00
Vaxart00203.00

Mesoblast currently has a consensus price target of $19.05, indicating a potential upside of 8.61%. Vaxart has a consensus price target of $19.50, indicating a potential upside of 163.51%. Given Vaxart's higher possible upside, analysts clearly believe Vaxart is more favorable than Mesoblast.

Summary

Mesoblast beats Vaxart on 7 of the 13 factors compared between the two stocks.

SpringWorks Therapeutics (NASDAQ:SWTX) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares SpringWorks Therapeutics and Vaxart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpringWorks TherapeuticsN/A-20.90%-20.20%
Vaxart-281.50%-84.90%-44.67%

Insider and Institutional Ownership

80.3% of SpringWorks Therapeutics shares are held by institutional investors. Comparatively, 17.9% of Vaxart shares are held by institutional investors. 51.2% of SpringWorks Therapeutics shares are held by company insiders. Comparatively, 36.7% of Vaxart shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares SpringWorks Therapeutics and Vaxart's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-12.72
Vaxart$9.86 million81.96$-18,650,000.00($0.86)-8.60

Vaxart has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for SpringWorks Therapeutics and Vaxart, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpringWorks Therapeutics00603.00
Vaxart00203.00

SpringWorks Therapeutics currently has a consensus price target of $46.40, indicating a potential upside of 2.77%. Vaxart has a consensus price target of $19.50, indicating a potential upside of 163.51%. Given Vaxart's higher possible upside, analysts clearly believe Vaxart is more favorable than SpringWorks Therapeutics.

Summary

SpringWorks Therapeutics beats Vaxart on 6 of the 11 factors compared between the two stocks.

Editas Medicine (NASDAQ:EDIT) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Editas Medicine and Vaxart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Editas Medicine-404.88%-46.57%-26.36%
Vaxart-281.50%-84.90%-44.67%

Insider and Institutional Ownership

86.3% of Editas Medicine shares are held by institutional investors. Comparatively, 17.9% of Vaxart shares are held by institutional investors. 0.9% of Editas Medicine shares are held by company insiders. Comparatively, 36.7% of Vaxart shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Editas Medicine and Vaxart's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$20.53 million89.20$-133,750,000.00($2.68)-10.97
Vaxart$9.86 million81.96$-18,650,000.00($0.86)-8.60

Vaxart has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Editas Medicine has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Vaxart has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Editas Medicine and Vaxart, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Editas Medicine04302.43
Vaxart00203.00

Editas Medicine currently has a consensus price target of $45.00, indicating a potential upside of 53.01%. Vaxart has a consensus price target of $19.50, indicating a potential upside of 163.51%. Given Vaxart's stronger consensus rating and higher possible upside, analysts clearly believe Vaxart is more favorable than Editas Medicine.

Summary

Editas Medicine beats Vaxart on 8 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IMVT
Immunovant
1.8$35.63+2.7%$3.13 billionN/A-23.14
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$9.64+4.7%$2.33 billion$31.43 million-5.91
RVMD
Revolution Medicines
1.7$32.87+4.4%$2.17 billion$50.04 million0.00Insider Selling
Mesoblast logo
MESO
Mesoblast
1.0$17.54+2.1%$2.06 billion$32.16 million-24.03Increase in Short Interest
SWTX
SpringWorks Therapeutics
1.3$45.15+0.4%$1.94 billionN/A-15.05
Editas Medicine logo
EDIT
Editas Medicine
1.3$29.41+1.1%$1.83 billion$20.53 million-11.67
NanoString Technologies logo
NSTG
NanoString Technologies
0.9$43.69+2.4%$1.66 billion$125.57 million-24.41
CRTX
Cortexyme
1.4$48.84+1.3%$1.44 billionN/A-23.94Heavy News Reporting
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$9.97+1.6%$1.41 billion$102.43 million-12.01Heavy News Reporting
BEAM
Beam Therapeutics
1.3$26.76+2.5%$1.38 billion$20,000.00-1.90Analyst Downgrade
Coherus Biosciences logo
CHRS
Coherus Biosciences
1.4$18.41+2.3%$1.32 billion$356.07 million7.87
Compugen logo
CGEN
Compugen
1.2$16.09+3.6%$1.10 billion$17.80 million-42.34
BDTX
I-Mab
1.5$29.65+9.2%$1.06 billionN/A-1.75Analyst Downgrade
Regenxbio logo
RGNX
Regenxbio
1.6$27.85+3.0%$1.04 billion$35.23 million-7.63Analyst Report
Analyst Revision
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.4$7.87+1.5%$1.02 billion$1.12 million-6.96Increase in Short Interest
TBIO
Translate Bio
1.2$13.13+3.7%$974.82 million$7.80 million-7.68Increase in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$12.97+3.2%$963.78 millionN/A-2.59Analyst Report
Decrease in Short Interest
ALEC
Alector
1.4$11.29+1.0%$894.87 million$21.22 million-5.56Heavy News Reporting
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.4$10.81+2.9%$871.90 million$250,000.00-8.93Analyst Downgrade
Increase in Short Interest
Heavy News Reporting
Replimune Group logo
REPL
Replimune Group
1.5$21.36+3.4%$860.55 millionN/A-12.87Increase in Short Interest
Vericel logo
VCEL
Vericel
1.7$18.28+1.6%$827.17 million$117.85 million-1,828.00Analyst Report
Krystal Biotech logo
KRYS
Krystal Biotech
1.4$41.39+0.9%$813.89 millionN/A-33.38
Nantkwest logo
NK
Nantkwest
2.0$7.18+4.6%$775.23 million$40,000.00-10.11Analyst Downgrade
Increase in Short Interest
Cellectis logo
CLLS
Cellectis
1.3$17.85+2.8%$758.02 million$22.99 million-11.52
Agenus logo
AGEN
Agenus
1.5$4.02+2.0%$737.44 million$150.05 million-3.53Analyst Report
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
2.1$3.64+5.8%$642.70 million$48.83 million-4.33
TCRR
Tcr2 Therapeutics
1.6$18.53+2.6%$617.86 millionN/A-7.59Analyst Upgrade
Heavy News Reporting
PASG
Passage Bio
1.6$13.34+6.1%$606.80 millionN/A0.00Heavy News Reporting
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.4$12.77+2.6%$574.43 million$2.91 million-4.63Analyst Report
Decrease in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.4$18.03+4.1%$538.65 million$20.49 million-8.31Decrease in Short Interest
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.6$11.21+3.8%$521.42 million$69.89 million-2.54Heavy News Reporting
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.73+2.6%$509.05 millionN/A-9.39Analyst Report
Increase in Short Interest
Avrobio logo
AVRO
Avrobio
1.6$13.59+3.6%$495.26 millionN/A-4.75Analyst Downgrade
Heavy News Reporting
OYST
Oyster Point Pharma
1.6$19.08+4.4%$491.37 millionN/A-1.74Analyst Downgrade
Heavy News Reporting
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.4$14.95+5.1%$471.34 millionN/A-12.89
MeiraGTx logo
MGTX
MeiraGTx
1.5$12.30+1.8%$459.57 million$13.29 million-7.99
BVXV
BIONDVAX PHARMA/S
0.5$39.62+3.0%$449.85 millionN/A-13.12Increase in Short Interest
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.4$11.52+0.5%$431.21 million$104.39 million-7.02
ORTX
Orchard Therapeutics
1.5$4.42+3.4%$429.91 million$2.51 million-2.42
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$4.98+6.6%$402.22 millionN/A-2.24Heavy News Reporting
PRVL
Prevail Therapeutics
1.7$11.39+7.5%$389.71 millionN/A-4.81Analyst Report
HARP
Harpoon Therapeutics
1.5$15.47+0.7%$388.95 million$5.78 million-6.88Increase in Short Interest
Proteon Therapeutics logo
PRTO
Proteon Therapeutics
0.8$16.95+0.4%$375.93 millionN/A-14.74Heavy News Reporting
PDL BioPharma logo
PDLI
PDL BioPharma
0.8$3.27+3.1%$372.72 million$54.76 million-2.46
Sutro Biopharma logo
STRO
Sutro Biopharma
1.4$10.30+0.2%$369.55 million$42.74 million-9.36Insider Selling
Increase in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.7$18.43+0.6%$358.15 million$340,000.00-6.65
DTIL
Precision BioSciences
1.6$6.13+3.8%$320.88 million$22.24 million-3.19High Trading Volume
Increase in Short Interest
IPHA
Innate Pharma
1.2$3.87+2.6%$295.84 million$96.12 million-11.37Increase in Short Interest
Eiger Biopharmaceuticals logo
EIGR
Eiger Biopharmaceuticals
2.0$9.89+6.2%$289.21 millionN/A-3.70
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
2.0$8.23+4.1%$280.38 million$147.87 million13.27Decrease in Short Interest
This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.